Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview

被引：28

作者：

Rezaee, Haleh ^{[1
,2
]}

Pourkarim, Fariba ^{[2
]}

Pourtaghi-Anvarian, Samira ^{[2
]}

Entezari-Maleki, Taher ^{[2
]}

Asvadi-Kermani, Touraj ^{[3
]}

Nouri-Vaskeh, Masoud ^{[4
,5
]}

机构：

[1] Tabriz Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tabriz, Iran

[2] Tabriz Univ Med Sci, Fac Pharm, Dept Clin Pharm, Tabriz, Iran

[3] Tabriz Univ Med Sci, Fac Med, Dept Surg, Tabriz, Iran

[4] Tabriz Univ Med Sci, Immunol Res Ctr, Daneshgah St,POB 5166614766, Tabriz, Iran

[5] Universal Sci Educ & Res Network USERN, Network Immun Infect Malignancy & Autoimmun NIIMA, Tehran, Iran

来源：

PHARMACOLOGY RESEARCH & PERSPECTIVES | 2021年 / 9卷 / 01期

关键词：

adverse reactions; chloroquine; COVID-19; drug-drug interaction; Kaletra; remdesivir; PLUS RIBAVIRIN TREATMENT; PHARMACOKINETIC INTERACTIONS; HEPATITIS-C; RHEUMATOID-ARTHRITIS; PROTEASE INHIBITORS; COINFECTED PATIENTS; HEALTHY-VOLUNTEERS; CHLOROQUINE; TOCILIZUMAB; METABOLISM;

D O I：

10.1002/prp2.705

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Drug-drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID-19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT-prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID-19 in order to minimize the adverse reactions.

引用

页数：18

共 50 条

[41] The another side of COVID-19 in Alzheimer's disease patients: Drug-drug interactions
Balli, Nisa
Kara, Emre
Demirkan, Kutay
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2020, 74 (10)
[42] Potential Drug-Drug Interactions in Hospitalized COVID-19 Patients (CATCO-DDI)
Tseng, A.
Sheehan, N. L.
Hewlett, K.
Wong, A. Y. J.
Coburn, B.
Kulikova, M.
Fowler, R.
Cheng, M. P.
Murthy, S.
CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2021, 74 (02): : 178 - 178
[43] Risk of drug-drug interactions in China's fight against COVID-19 and beyond
Zhang, Qingpeng
Yang, Jiannan
Zeng, Daniel Dajun
Feng, Yibin
Wong, Ian C. K.
PHARMACOLOGICAL RESEARCH, 2023, 196
[44] Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients
Cattaneo, Dario
Pasina, Luca
Maggioni, Aldo Pietro
Oreni, Letizia
Conti, Federico
Pezzati, Laura
Casalini, Giacomo
Bonazzetti, Cecilia
Morena, Valentina
Ridolfo, Annalisa
Antinori, Spinello
Gervasoni, Cristina
DRUGS & AGING, 2021, 38 (04) : 341 - 346
[45] Physicians' knowledge of potential covid-19 drug-drug interactions: An online survey in turkey
Surmelioglu, Nursel
Yalcin, Nadir
Kuscu, Ferit
Candevir, Aslihan
Inal, Ayse Seza
Komur, Suheyla
Kurtaran, Behice
Demirkan, Kutay
Tasova, Yesim
POSTGRADUATE MEDICINE, 2021, 133 (02) : 237 - 241
[46] OOPS, I CLOTTED AGAIN! A CASE OF RECURRENT VTE AND POTENTIAL DRUG-DRUG INTERACTIONS IN TREATMENT OF COVID-19
Santone, Daniel
Closser, Douglas
CHEST, 2021, 160 (04) : 897A - 897A
[47] Assessment of used medications and drug-drug interactions among chronic renal failure patients
Sgnaolin, Vanessa
Sgnaolin, Valeria
Engroff, Paula
DeCarli, Geraldo Attilio
Prado Lima Figueiredo, Ana Elizabeth
SCIENTIA MEDICA, 2014, 24 (04) : 329 - 335
[48] Drug-Drug Interactions between COVID-19 and Tuberculosis Medications: A Comprehensive Review of CYP450 and Transporter-Mediated Effects
Jony, M. Rasheduzzaman
Ahn, Sangzin
PHARMACEUTICALS, 2024, 17 (08)
[49] COVID-19 Drug Interactions
Surmelioglu, Nursel
Demirkan, Kutay
JOURNAL OF CRITICAL & INTENSIVE CARE, 2020, 11 : 43 - 45
[50] Treatment of bipolar disorder with somatic comorbidities - an overview of drug-drug interactions
Marinescu, V.
Vrabie, M.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S140 - S141

← 1 2 3 4 5 →